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A B S T R A C T 
 
Background: Non-pharmacological treatment is needed to reduce serum lipid levels and 
prevent atherosclerosis. Foods that contain Isoflavones can improve lipid profiles in the serum. 
Aim: To determine the effect of soya and genistein supplementation in various doses on total 
cholesterol, Low Density Lipoprotein Cholesterol (LDLC), High Density Lipoprotein Cholesterol 
(HDLC), Triglycerides in male Sprague-Dawley rats. 
Methods: This study of 35 male Sprague-Dawley rats aged 6-8 weeks were divided into 7 
groups, control group; low, medium, and high doses of soy milk; and low, moderate, and high 
doses of genistein. The treatment was given orally for 60 days. The control used was mice with 
standard feed. On day 61, serum and hepatic tissue samples were taken and checked for lipid 
profiles using the Friedewald formula. Statistical analysis was carried out by one-way ANOVA 
and Tukey's posthoc test and Dunnet test, then regression analysis. 
Results: There was a significant increase in total cholesterol levels (p <0.05) and LDLC levels in 
low and moderate doses of soy milk group compared to all groups of genistein. There was no 
significant differences in HDLC levels in soya and genistein groups. There was significant 
increase in Triglyceride levels in all groups of soy milk and low and moderate doses of Genistein 
compared to high doses of genistein. 
Conclusion: In this study, Soya and genistein supplementation had increased effect on the 
Total Cholesterol, LDLC and Triglycerides but no effect on HDLC.  
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I N T R O D U C T I O N 
The prevalence of coronary heart 
disease (CHD) in Indonesia in 2013 based on 
physician’s diagnosis was around 883,447 
people.(1) The most common cause of CHD is 
atherosclerosis, which is a chronic 
inflammatory response to cholesterol 
deposition on the walls of arterial blood 
vessels.(2) 
Currently, atherosclerosis therapy 
includes anti-inflammatory drugs such as 
cyclooxygenase (COX) inhibitors and 
immunosuppressant drugs, but these drugs 
only work to inhibit the progression of existing 
atherosclerotic plaques, not prevent their 
formation.(3) Soybeans contain genistein 
isoflavone phytoestrogens which can reduce 
cholesterol levels in the blood by increasing 
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HDLC, lowering LDLC and triglycerides in the 
blood.(4) 
In 2015, soybean consumption in 
Indonesia reached 2.54 million tons of dry 
beans, consisting of direct consumption of 2.3 
million tons of residents, 39,000 tons of seeds, 
446,000 tons of non-food industry, and 49,000 
tons of soy milk, indicating easy access for 
residents. Indonesia against soybeans.(5) 
M E T H O D S  
The design study is Post Test Control 
Group Design with regression analysis. This 
study used experimental animals, Sprague 
Dawley mice. Inclusion criteria: male mice, age 
6-8 weeks, body weight 160-200 grams, have 
not experienced any treatment or have not 
received any chemical intake, and are in good 
health with active. Exclusion criteria: mice do 
not want to eat, rats that have decreased 
physical condition or die.  
A total of 35 experimental animals were 
divided into 7 groups, the control group; low 
doses of soy milk (0.8 ml), medium doses of soy 
milk (1.6 ml), and high doses of soy milk (2x1.6 
ml); and low doses of genistein (0.8 ml), 
moderate doses of genistein (1.6 ml), and high 
doses of genistein (2x1.6 ml). The treatment 
was given orally for 60 days. The control used 
was mice with standard feed. 
On the 61st day, rats were sacrificed, 
blood samples were taken, then checked for 
lipid profiles using Friedewald's formula and 
made liver histological preparations by staining 
with Oil Red O. The making of slides and 
reading of slides was carried out at the 
Histopathology Laboratory of the Faculty of 
Medicine, Universitas Brawijaya. The study was 
carried out in February-April 2019.  
All technical data processing results 
were analyzed in a computerized manner using 
the Statistical Product and Service Solution 
software, IBM SPSS Statistics 20 with a 
significance level or a probability value of 0.05 
(p = 0.05) and a confidence level of 95% (α = 
0.05). The steps of the comparative hypothesis 
test are as follows: data normality test using the 
Kolmogorov-Smirnov test, variant 
homogeneity test using the Barlett 
homogeneity test, One-way ANOVA test, and 
post hoc test using the Tukey-HSD test. 
R E S U L T S  
The study used 35 male Sprague 
Dawley rats, divided into 7 groups, each 
consisting of 5 rats. Four subjects were 
excluded from the study because they died 
from infection. Characteristic between groups 
is shown at Table 1. 
At the end of the study there were 31 
subjects for data analysis which were divided 
into each group as follows: Group K1: 5 
subjects, K2: 4 subjects, K3: 5 subjects, K4: 5 
subjects, K5: 3 subjects, K6 4 subjects, K7: 4 the 
subject. Subjects who had extreme body 
weight scores at the start and end of the study 
were excluded from the data analysis. 
Determination of extreme values using Box Plot 
analysis. 
Effect of Soybean Milk and Genistein on Lipid 
Profiles 
Effect of Soybean Milk and Genistein on 
Lipid Profiles and Lipid Infiltration is shown at 
Table 2. There is a significant effect of giving 
soy milk and genistein on total cholesterol with 
different doses. Based on the results of Tukey's 
5% test, comparison of the Control group (K) 
with all treatment groups with soy milk and 
genistein, the p-value was less than 0.05 (p 
<0.05) for 0.8 ml and 1.6 ml soy milk. From this 
test it was proven that the mean total 
cholesterol of soy milk giving 0.8 ml and 1.6 ml 
was higher than the control group. 
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  Starting from the control group, it 
appears that the mean total cholesterol is 
higher in all treatment groups with soy milk and 
genistein, except that the 2x 1.6 ml of genistein 
has lower total cholesterol than the control 
group. The highest average total cholesterol 
was found in the provision of 1.6 ml soy milk 
and the lowest average total cholesterol was 
found in the administration of genistein 2x 1.6 
ml, namely 31.16 ± 20.58 mg/dL. 
The effect of soy milk and genistein 
doses on total cholesterol levels forms a non-
linear pattern. Increasing the dose of soy milk 
and genistein does not always increase or 
decrease total cholesterol levels. It is shown in 
Figure 1. 
It can be seen that there was an 
increase in total cholesterol levels at the 
addition of 1.6 ml doses of soy milk and 
genistein. Then, by increasing the dose of 
gensitein 2x1.6 ml, there was a decrease in total 







Figure 1. Regression analysis effect of soya milk and 
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Soy milk affects total cholesterol by 
52.05%, while the remaining 47.95% is 
explained by errors and other factors not 
examined. Genistein affects total cholesterol by 
51.01%, while the remaining 48.99% is 
explained by errors and other factors not 
examined. 
There is also a significant effect of 
giving soy milk and genistein on HDLC levels at 
different doses. Based on the results of the 
Dunnet T3 5% test, comparison of the Control 
(K) group with all treatment groups with soy 
milk and genistein, the p-value was less than 
0.05 (p< 0.05) in all groups. From this test it was 
proven that the mean HDLC levels of soy milk 
and genistein were not significantly different 
from the control group. Starting from the 
control group, it was seen that the mean HDLC 
lipid content was higher in the treatment group 
with 1.6 ml and 2x 1.6 ml soy milk, but this 
increase was not statistically significant. When 
compared with the genistein group, an increase 
in all genistein doses was shown, but it was not 
statistically significant. 
The effect of soy milk dose on HDLC 
lipid content formed a linear pattern. 
Increasing the dose of soy milk increases HDLC 
lipid levels. It can be seen that there is an 
increase in HDLC lipid levels along with the 
addition of the soy milk dose. Soy milk has an 
effect on HDLC lipid content by 55.88%, while 
the remaining 44.12% is explained by errors 
and other unexamined factors. It is shown in 
Figure 2. 
 
The effect of genistein dose on HDLC 
lipid levels forms a non-linear pattern. 
Increasing the dose of genistein does not 
always increase or decrease HDLC lipid levels. It 
can be seen that there was a decrease in HDLC 
lipid levels at the addition of 1.6 ml genistein 
dose. Then, by increasing the dose to 2x1.6 ml, 
there was an increase in HDLC lipid levels. 
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Figure 2. Regression analysis effect of soya milk and 
geni t in on HDLC. 
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while the remaining 29.66% is explained by 
errors and other factors not examined. 
There is a significant effect of giving soy 
milk and genistein on LDLC lipid levels at 
different doses. Based on the results of the 5% 
Dunn test, it was shown that the Control group 
had an average LDLC lipid content of 19.33 ± 
5.87 with the letter "ab" notation. When 
compared with the soy milk group with various 
doses, it was shown that there was an increase 
in LDLC lipid levels at all doses of soy milk and 
a significant increase occurred in the 1.6 ml and 
2x 1.6 ml soy milk. This can be seen from the 
mean ± SD for the soy milk group of 1.6 ml and 
2x 1.6 ml higher and has a different letter than 
the control group.  
In the comparison between the Control 
group and the group given genistein, It was 
shown that the 0.8 ml and 1.6 ml genistein 
group had a higher mean than the control 
group. This proved that there was an increase 
in LDLC lipid levels in the two doses of genistein 
but it was not statistically significant. This can 
be seen from the mean ± SD of the group giving 
genistein 0.8 ml and 1.6 ml higher but it has the 
same letter as the control group. 
Starting from the control group, it was 
seen that the mean LDLC lipid content was 
higher in the treatment group with all doses of 
soy milk, and statistically significant increases 
occurred at doses of 1.6 ml and 2x 1.6 ml. When 
compared with the genistein group, it was 
shown that there was an increase in the 
administration of genistein 0.8 and 1.6 ml but it 
was not statistically significant. 
The effect of soy milk and genistein 
doses on LDLC levels formed a non-linear 
pattern. Increasing the dose of soy milk and 
genistein does not always increase or decrease 
LDLC levels. It is shown in Figure 3. 
 
It can be seen that there is an increase 
in LDLC levels at the addition of 1.6 ml doses of 
soy milk and genistein. Then, by increasing the 
dose to 2x1.6 ml, there was a decrease in LDLC 
levels.  
Soy milk has an effect on LDLC lipid 
content by 80.34%, while the remaining 29.66% 
is explained by errors and other factors not 
examined. Genistein affects LDLC lipid levels by 
72.88%, while the remaining 27.12% is 
explained by errors and other factors not 
examined. 
There is no significant effect of giving 
soy milk and genistein on Tryglicerida levels 
with different doses. Based on the results of the 
Tukey 5% test, the comparison of the Control 
group (K) with all treatment groups giving soy 
milk and genistein, obtained a p-value more 
than 0.05 (p>0.05) when giving Genistein 0.8 ml 
and 1.6 ml. The difference in mean value is 
negative, indicating that the mean of the 
control group is lower than the group giving 
Genistein 0.8 and 1.6 ml. From this test, it was 
proven that the average Tryglyceride levels 
were 0.8 and 1.6 ml higher than the control 
group. 
Starting from the control group, it 
appears that the mean Tryglicerida levels were 
higher in the treatment group with all doses of 
 
Figure 3. Regression analysis effect of soya milk and 
genistein on LDLC 
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soy milk and 0.8 ml and 1.6 ml of genistein. The 
average decrease in Tryglicerida levels was 
found in the group given 2x 1.6 ml of genistein 
with an average Tryglycerida level of 0.49 ± 0.06 
mg / dL, but the decrease was not significant 
(p> 0.05). 
The effect of soy milk and genistein 
doses on Tryglycerida levels formed a linear 
pattern. Increasing the dosage of soy milk and 
genistein increases TG levels. It can be seen that 
there is an increase in triglyceride levels along 
with the addition of soy milk and genistein 
doses. It is shown in Figure 4.  
Soy milk has an effect on Triglyceride 
levels by 73.68%, while the remaining 26.32% is 
explained by errors and other factors not 
examined. Genistein affects Triglyceride levels 
by 73.68%, while the remaining 26.32% is 
explained by errors and other factors not 
examined. 
D I S C U S S I O N S  
In this study, 4 subjects were excluded 
due to death. The proportion of sample deaths 
reached 11.3%, exceeding the initial estimate 
of 10%. In group 5, there were 2 rats that died 
due to infection so that the number of samples 
was only 3, less than the minimum sample 
requirement in the calculation of the 
Federation formula. Data from subjects who 
had extreme body weight scores at the start 
and end of the study were not used in the data 
analysis.  
In this study, the total number of 
samples used for data analysis was 25 samples. 
So there are several groups that do not meet 
the minimum sample requirements, namely 
groups K1, K4, K5 (n = 3). One way ANOVA test 
results showed the effect of giving soy milk and 
genistein on body weight (p = 0.022).  
Post hoc test with Tukey HSD, showed 
no effect of soy milk on body weight and BMI 
between the control and treatment groups at 
all doses. Genistein also did not significantly 
affect differences in body weight and BMI 
between control and treatment groups at all 
doses. Study by Wang et al showed that 
supplementation of soy milk and genistein in 
large doses in male rats tended to lose weight. 
Whereas at low doses it tends to increase body 
weight. (6) 
However, there is a gap between invitro 
and invivo studies due to the overlapping of 
transcription factors, metabolism and the 
stability of active substances. The use of soy 
milk and genistein also gave different results, 
because in soy milk there is another isoflavone, 
daidzein, which influences lipogenesis through 
the PPAR-α independent pathway in 
hepatocytes rather than through estrogen 
receptors in adipocyte tissue. Microarray gene 
analysis showed that adipogenesis in low-dose 
genistein was influenced by the phospholipase 
A2 group 7 gene and phospholipid transfer 
protein. Meanwhile, the anti-adipogenic 
activity of genistein and down-regulation of the 
adipogenic gene require expression of Erβ.(7) 
In this study all groups of mice were 
obese. This result is not in accordance with the 
initial study design, because the control used is 
 
Figure 4. Regression analysis effect of soya milk and 
genistein on Triglycerides 
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a negative control, so it is expected that obesity 
does not occur in the control group. This study 
did not calculate the amount of leftover feed, 
and the physical activity of rats. Obesity that 
occurred in all groups in this study could occur 
due to excess calorie intake compared to daily 
calorie requirements compared to physical 
activity of rats. Daily calorie requirements for 
male Sprague Dawley rats 110 kcal ME/BW 
0.75kg/day. (8,9) 
While the food intake given in this study 
in all groups was 70-80 g/cage/day which was 
equivalent to 120-137 kcal/rat/day. 
The Effect of Soybean Milk and Genistein on 
Lipid Profile 
From the results of this study, it was 
found that giving soy milk to male Sprague 
dawley rats, the results were more increased 
total cholesterol, LDLC and triglycerides; and 
HDLC decreased more than genistein.  
Several studies have shown that 
supplementing the diet with soy protein will 
lower blood cholesterol and reduce chronic 
disease in populations in the West and in 
Japan.(10)  
Isoflavones increase HDLC and reduce 
total cholesterol, LDLC and TG, presumably due 
to the role of soy isoflavones, namely genistein, 
daidzein and glycetein, which have biological 
activity as phytoesterogens, antioxidants and 
antimutagen.(11)  
In the liver, isoflavones are presumed to 
bind to ER, thereby increasing the density and 
number of LDLC receptors via an up-regulation 
mechanism. So that the uptake of LDLC in 
plasma by the liver increases and decreases the 
total cholesterol fraction in the blood.(12) 
 Isoflavones also aid in the transport of 
LDLC to steoidogenic tissues such as the 
adrenal glands, testes, and ovaries. After 
binding to the estrogen receptor on 
lipoproteins, cholesterol is absorbed by 
steroidogenic cells and then stored and 
transferred to the steroid synthesis site. 
Increased HDLC by isoflavones, presumably by 
means of isoflavones that bind to ER in the liver 
will increase the production of nascent HDL. 
Nascent HDLC will approach macrophages to 
take cholesterol stored in macrophages. After 
taking up cholesterol in macrophages, nascent 
HDLC turns into mature, spherical HDLC 
remmant. Furthermore, some of the 
cholesterol esters carried by HDLC will take two 
pathways13: The first route is to the liver and is 
captured by the class B type 1 (SR-B1) receptor 
scavenger. The second pathway is that 
cholesterol esters in HDLC will be exchanged 
with triglycerides and VLDLC and IDLC with the 
help of cholesterol ester transfer protein 
(CETP). (13) 
Apart from being estrogenic, 
isoflavones also act as antioxidants. Soy 
isoflavones can reduce the Thiobarbitoric Acid 
Reactive Substance (TBARS), a radical that 
causes mutagenesis, carsiogenesis and cell 
death.(14) 
Isoflavones interfere with the hydrogen 
peroxide reaction by donating hydrogen atoms 
to free radicals, so that free radicals do not 
form. This is very useful when there are 
excessive levels of LDLC in the plasma, most of 
the LDLC will be oxidized and then eaten by 
macrophages to become foam cells. Isoflavone 
antioxidants prevent LDLC oxidation, so that a 
lot of LDLC is captured by liver cells, so that 
total cholesterol falls. The lower the foam cell, 
the lower the risk of atherosclerosis, so that 
isoflavones are also called cardioprotective. 
Soybean intake can reduce the direct 
absorption of cholesterol and TG in the 
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intestine, so that cholesterol ester and TG levels 
decrease. This also results in a decrease in total 
cholesterol levels in the blood.(14) 
The reduction in total cholesterol levels 
studied varied, depending on the factors and 
treatment of the study, including the form and 
type of isoflavones, isoflavone intake levels, 
study time, gender of the subject, lipid levels 
and menopause status.(15)  
Another form of isoflavones are tablets. 
In one isoflavone tablet contains daidstein, 
genistein, biochanin, formonectin or contains 
daidstein and genistein or contains only 
genistein. From the results of study on 
isoflavone tablet form shows that Isoflavone 
tablets, up to 150 mg per day, have a significant 
effect in lowering serum total cholesterol, LDL-
cholesterol and triglycerides. There are also 
significant benefits over serum HDL-
cholesterol.(16,17)  
The results were consistent when the 
tablet was introduced as isolated genistein 
only, but the mixture of genistein and daidzein, 
or a mixture of genistein, daidzein, formonectin 
and biochanin did not give a significant effect. 
It is thought that each composition of the 
isoflavone combined influence each other so 
that it gives insignificant results.(16-19) 
A meta-analysis of 17 studies by Yeung, 
showed that the level of isoflavone intake 
(<50g/hr; 51-100g/day; and 101-150g/day) had 
no significant effect on reducing total 
cholesterol. It is suspected that isoflavones, 
especially genistein, which bind to estrogen 
receptors, have a low affinity, besides that 
isoflavones must compete with endogenous 
estrogens against estrogen receptors. (20,21) 
Treatment time also affects total 
cholesterol levels in isoflavone intake. The 
treatment time of 11-20 weeks gave significant 
results compared to 2-10 weeks, this is thought 
to be an adaptation time until it reaches a 
certain affinity for the estrogen receptor. While 
the treatment time of 21-30 weeks gave 
insignificant results. This is presumably 
because the period 21-30 is the end of the 
duration of the isoflavones in the blood which 
will then be excreted through the kidneys.(22-26)  
The effect of gender turned out to have 
an effect on total cholesterol levels in 
isoflavone intake. A man has a decrease in total 
cholesterol that is more significant than a 
woman. This is presumably because 
isoflavones in women have to compete with 
endogenous estrogens whose levels are higher 
than endogenous estrogens in men. This was 
the exception to the variable for women with 
peri- or postmenopausal status 
(hypoesterogen).(25,27) 
 Apart from these factors, it is also 
necessary to consider several factors that have 
not been discovered or researched. These 
factors, namely body weight and lipid 
distribution, intake of other proteins, and 
physical activity may have an effect on reducing 
total cholesterol in the blood. 
Limitations 
There are several limitations: 1. The 
number of samples is too small. In this study, 
the sample size was reduced because the 
deaths that occurred exceeded the estimated 
number and there were extreme values that 
were not used in data analysis. 2. Negative 
control in study becomes obesity due to factors 
that are beyond the knowledge of researchers 
and are not considered when making study 
designs and proposals. 3. The content of other 
isoflavones in soy milk was not checked. 
Examination is necessary because the 
isoflavone compounds other than genistein in 
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soy milk include phytoestrogens with different 
affinities. 
C O N C L U S I O N 
There was an increase in total cholesterol, 
Low Density Lipoprotein Cholesterol (LDCL) 
and Triglycerides in Sprague Dawley male rats 
in the soy milk and genistein supplementation 
group. There was no effect on High Density 
Lipoprotein Cholesterol (HDCL) and liver lipid 
infiltration in Sprague Dawley male rats in the 
soy milk and genistein supplementation group.  
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